204 related articles for article (PubMed ID: 1807008)
1. The structure-function relationship of GLP-1 related peptides in the endocrine function of the canine pancreas.
Ohneda A; Ohneda K; Ohneda M; Koizumi F; Ohashi S; Kawai K; Suzuki S
Tohoku J Exp Med; 1991 Nov; 165(3):209-21. PubMed ID: 1807008
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
3. Effect of glicentin-related peptides upon the secretion of insulin and glucagon in the canine pancreas.
Ohneda A; Ohneda M
Tohoku J Exp Med; 1988 Jun; 155(2):197-204. PubMed ID: 3062845
[TBL] [Abstract][Full Text] [Related]
4. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets.
Fehmann HC; Hering BJ; Wolf MJ; Brandhorst H; Brandhorst D; Bretzel RG; Federlin K; Göke B
Pancreas; 1995 Aug; 11(2):196-200. PubMed ID: 7479679
[TBL] [Abstract][Full Text] [Related]
5. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
[TBL] [Abstract][Full Text] [Related]
7. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
Fehmann HC; Göke R; Göke B; Bächle R; Wagner B; Arnold R
Biochim Biophys Acta; 1991 Feb; 1091(3):356-63. PubMed ID: 1705823
[TBL] [Abstract][Full Text] [Related]
8. Glucagonlike peptide I (7-37) actions on endocrine pancreas.
Weir GC; Mojsov S; Hendrick GK; Habener JF
Diabetes; 1989 Mar; 38(3):338-42. PubMed ID: 2645190
[TBL] [Abstract][Full Text] [Related]
9. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.
Fehmann HC; Habener JF
FEBS Lett; 1991 Feb; 279(2):335-40. PubMed ID: 1672112
[TBL] [Abstract][Full Text] [Related]
10. Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets.
van der Burg MP; Guicherit OR; Frölich M; Gooszen HG
Regul Pept; 1995 Dec; 60(1):61-7. PubMed ID: 8747785
[TBL] [Abstract][Full Text] [Related]
11. Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development.
García-Flores M; Zueco JA; Alvarez E; Blázquez E
Eur J Biochem; 2001 Feb; 268(3):514-20. PubMed ID: 11168389
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.
Siegel EG; Scharf G; Gallwitz B; Mentlein R; Morys-Wortmann C; Fölsch UR; Schmidt WE
Eur J Clin Invest; 1999 Jul; 29(7):610-4. PubMed ID: 10411667
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases.
Kawai K; Suzuki S; Ohashi S; Mukai H; Ohmori H; Murayama Y; Yamashita K
Endocrinology; 1989 Apr; 124(4):1768-73. PubMed ID: 2564338
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
17. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.
Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB
Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of glucagon-like peptide 1 insulinotropic action by succinic acid dimethyl ester.
Leclercq-Meyer V; Malaisse WJ
Life Sci; 1996; 58(14):1195-9. PubMed ID: 8614271
[TBL] [Abstract][Full Text] [Related]
19. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
20. Effect of C-terminal fragments of glucagon on insulin secretion in dogs.
Ohneda A; Ohneda K
Metabolism; 1994 Jun; 43(6):771-5. PubMed ID: 8201969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
